Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (August 2023)
19 slides from Enveric Biosciences's investor presentation, Aug 28, 2023
Slide 1: Corporate Presentation Q3 2023
jllNasdaq:ENVB = A EIN EIA 6 reraicair BIOSCIENCES CORPORATE PRESENTATION Q3 2023 Enveric.com
Slide 2: Disclaimer
Disclaimer
Slide 3: Slide 3
Slide 4: Mental Health Epidemic
Mental Health Epidemic 222A 1in4 experiences o mental ilness in any given year 9) 40% First line SSRIs treatments work {or less than half of patients TARGETED DISORDERS: a Mentalillness ond eubstence use disorders are the leading causes of disability People with severe mental health conditions die 1
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A new Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala This modulates the fight-or-flight thoughts and emotions that originate in the amygdala . Neuroplastogens stimulate Neuropsyc
Slide 6: Our Portfolio of Neuroplastogen Molecules
Our Portfolio of Neuroplastogen Molecules + The Psybrary™: Our library of 500+ potential neuroplastogen drug candidates + We combined synthetic biology HO. N and chemistry technologies to create a highly diverse portfolio for drug discovery Z2~ + Molecules are designed based on structures of known s
Slide 7: Distinct Neuroplastogen Treatment Paradigms
Distinct Neuroplastogen Treatment Paradigms In Clinic — + High dose + Clinical setting + One course of therapy potentially provides benefit for months + Treatment is associated with hallucinations; + Time consuming “Appropriate for a limited patient population Prescription Model + Moderate dose * Pr
Slide 8: Pipeline Programs
Pipeline Programs /; Y PROGRAM | INDICATION | PERFORMANCE GOALS DISCOVERY BHT2aR ligand, Brain- In Clinic: Anxiety targeted, Faster-acting, EB-373 Shorter duration, Reduced | = Glupset PRE-CLINICAL. PHASE | NEXT MILESTONE Initiate FIH in Australia SHT2AR ligand, Sub-clinical Prescription: anxiety, |
Slide 9: In Clinic Program: EB-373
In Clinic Program: EB-373 Synopsis of Target Benefits + Altered metabolic and pharmacokinetic properties relative to psilocybin to achieve improved risk/benefit profile + Flexible delivery route ~ potential for oral, intra-nasal, buccal or intravenous route for © Faster access to target receptor and
Slide 10: EB-373 Development
EB-373 Development £ miy aa ANT} Developed an improved Established Enveric Agreement with Positive results from Completed in-vitro formulation of EB-373 Therapeutics Pty. Ltd, an Avance Clinical, an animal studies metabolism designed to enhance the Australia-based Australia-based CRO, demonstrating
Slide 11: Anxiety Market: New Treatments Needed
Anxiety Market: New Treatments Needed + Anxiety disorders are among the most common CNS Disorders, ranking second. + Anxiety disorders are chronic conditions that remain poorly controlled despite available treatments. + The last FDA-approved drug to treat Generalized Anxiety Disorder was Cymbalta (D
Slide 12: Prescription Model Program: EVM301
Prescription Model Program: EVM301 Synopsis of Target Benefits + Reduced hallucination profile + Improved cardiac safety + Orally bioavailable, chronic administration + Treatment in clinic not required + Drug intended to be prescribed for regular maintenance and taken at times and in settings more c
Slide 13: Neuropsychiatric Market Rapidly Growing
Neuropsychiatric Market Rapidly Growing + Neuropsychiatric disorders continue to be a tremendous unmet need with limited innovation. + The last FDA-approved drug to treat Neurpsychiatric disorders was Esketamine (2019) and Brexpiprazole (2015) both as an adjunctive therapy. + The most widely used dr
Slide 14: Intellectual Property
Intellectual Property Psybrary™: Portfolio of 500+ drug candidates Patents © EB-373: © US Patent 11,707,447 and two more US and PCT applications ~ compositions of numerous molecules © Prodrug molecules other than EB-373 © One US Notice of Allowance, nine more US and six PCT ‘applications - compositi
Slide 15: Potential for Strategic Drug Development Deals
Potential for Strategic Drug Development Deals Example Partnership: 1 SAGE THERAPEUTICS R Urrontcomn ener capi CONTRACT faye Collaboration and License Agreement Partners: Biogen, Sage | Equity Investment: $650M at 40% premium Milestones: Sage-217, up to $475M; Sage-324 up to $520M; ations: PPD, MDD,
Slide 16: Competitive Landscape
Company Program Status Ticker Market Cap Progress Gen2 Pre-Clinical a Public NASDAQ:ENVB. $6.11M iosciences Gen3 Discovery Compass Gen1 Phase 3 P: He Public NASDAQ:CMPS_ $413.3M athways Gen2 Pre-Clinical Gen2 Phase 2 Cybin Inc. Public = NYSE:CYBN $129.4M Gen3 Pre-Clinical - $73.6 Total funding - Pit
Slide 17: Value Inflection Points
Value Inflection Points EB373 O File HREC for £8373 in Australia O First patient dosed in Phase 1 clinical trial - £8373 © Positive results from initial Phase 1 clinical trial for E8373 OfFile IND for £8373 in US EVM301 © Additional Notices of Allowance for EVM301 CO Lead candidate nomination for EV
Slide 18: The Future of Neuroplastogen Medicine
The Future of Neuroplastogen Medicine Pipeline provides multiple shots on goal + Patented molecules can address multiple psychological indications Strong IP Portfolio + One patent and two patent Notices of Allowance with 10+ more anticipated + Large number of molecules expected to act as neuroplasto
Slide 19: Next Generation Mental Health - Enveric.com
Nasdaq:ENVB _ a) L ENVERIA ? remer voc — Mental Health™ om W->—“SB=I=@.S -C J-E NNC/E*S\\ . =. - a Enveric.com
Enveric Biosciences — Investor Presentation (August 2023) on 6ix